Ibio shareholders meeting. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc.

Ibio shareholders meeting. In connection with the proposals, the Company filed a definitive proxy statement on Schedule 14A with the U. Proxy Information Thank you for being an iBio stockholder! Oct 26, 2021 · BRYAN, Texas, Oct. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on current activities including progress in developing IBIO-CFB03 to address significant unmet medical need for the treatment of idiopathic pulmonary Dec 10, 2014 · iBio, Inc. 00% retail investors. 30% institutional shareholders, 175. Provides Corporate Update at Annual Shareholders Meeting NEW YORK, NY -- (Marketwired) -- 05/04/17 -- iBio, Inc. By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us realize our vision of changing the biologic drug manufacturing paradigm with the FastPharming System and, as importantly, take advantage of Dec 23, 2021 · The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. 22, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. Proxy Information Thank you for being an iBio stockholder! Sep 3, 2024 · Discover iBio's upcoming investor presentations at H. The meeting will be held on November 20, 2025 at 1:00 p. Wainwright and Cantor Global Healthcare conferences. By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting - iBio’s Board Urges Shareholders to Vote Today to Support Company’s Strategic Growth Plans - Dec 22, 2021 · The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. , a Delaware corporation (the “ Company ”). The Dec 10, 2014 8:31am EST iBio Provides Updates on Its IBIO-CFB03 Fibrosis Drug Candidate and Other Activities for the 2014 Annual Shareholders Meeting 1… 11 12 13 14 15 16 17 18 19 20 Nov 15, 2021 · iBio Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9 Sep 27, 2021 7:30am EDT IBIO, INC. So please vote your shares so that we have Dec 10, 2014 · iBio, Inc. “Of course, our Board of Directors is elected to represent our shareholders, and the Board’s voting The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. Kay highlighted the Company's most important achievements since its last Dec 22, 2021 · The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us realize our vision of changing the biologic drug manufacturing paradigm with the FastPharming System and, as importantly, take advantage of NEWARK, DE-- (Marketwired - December 10, 2014) - iBio, Inc. Learn about their AI-driven antibody immunotherapies and schedule one-on-one meetings with key executives. ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting Nov 29, 2021 8:45am EST Nov 30, 2022 · iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022 Dec 21, 2021 9:20am EST Oct 14, 2021 · You are cordially invited to attend the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) of iBio, Inc. Securities and Exchange Commission on October 26, 2021 and the Definitive Additional Materials 19 hours ago · Tesla's (TSLA) shareholder meeting is scheduled for Thursday, Nov. The matters listed in this notice of meeting are described in detail in the accompanying Proxy Statement. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on current activities including progress in developing IBIO-CFB03 to address significant unmet medical need for the treatment of idiopathic Dec 10, 2021 · - Shareholders Presently Supporting Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - BRYAN, Texas, Dec. 56M. The Letters supplement the Definitive Proxy Statement filed by iBio with the U. By combining proprietary 3D… Oct 6, 2025 · You are cordially invited to attend the 2025 Annual Meeting of Stockholders (the “ 2025 Annual Meeting ”) of iBio, Inc. However, as is typical for companies with a large number of retail shareholders, many common shareholders simply didn’t vote their shares. Kay highlighted the Company's most important achievements since its last Annual Meeting - first, the creation of a new subsidiary for product development and large-scale manufacturing using the Company's Mar 2, 2020 · --IBIO, INC. The Company aims to secure the requisite majority from all outstanding Dec 23, 2014 · NEWARK, Del. Nov 17, 2021 · Tom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. As of now, shareholders are supporting these proposals by a 2-to-1 margin. 30, 2021 - ISS Joins Glass Lewis in Recommending Shareholders Vote "FOR" All Proposals Ahead of iBio's Upcoming Annual Meeting Oct 26, 2021 · This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBio’s 2021 Annual Meeting of Stockholders. Stock Equities IBIO US4510337086 Biotechnology & Medical Research Summary Quotes Charts The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. Currently, 64% and 67% of shareholders have voted in favor, but additional votes are necessary for approval. The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. (NYSE: IBIO) has partially adjourned its 2021 Annual Meeting of Shareholders to allow further voting on two key proposals: a Reverse Stock Split and a Change in Authorized Shares. The purpose of the 2025 Annual Meeting and the matters to be acted on are stated in the accompanying Notice of Annual Meeting of Stockholders. 77% Ibio insiders, and 0. The meeting will address two critical proposals: a reverse stock split and an increase in authorized shares. Shareholders are urged to read the definitive proxy Oct 12, 2014 · NEWARK, DE-- (Marketwired - Dec 10, 2014) - iBio, Inc. iBio subsequently received additional votes “FOR” the proposals, as well as support from a number of shareholders who changed their Read Press Release for Ibio (IBIO) published on Nov. We have important decisions on the ballot and our Bylaws require that a majority of the issued and outstanding shares of iBio capital stock be represented to achieve a quorum. Kay highlighted the Company's most important achievements since its last Annual Meeting - first, the creation of a new subsidiary for product development and large-scale manufacturing using the Company's Nov 17, 2021 · Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting November 17, 2021 16:30 ET | Source: iBio, Inc. m. Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting Download as PDF November 17, 2021 4:30pm EST IBIO - iBio Inc - Stock screener for investors and traders, financial visualizations. (NYSE MKT: IBIO) - Speaking to shareholders at the iBio, Inc. (NYSE MKT: IBIO), a leader in developing plant-based biopharmaceuticals, announced today that it provided a corporate update at its Annual How are you!!Meeting you is a day of beauty seconds!! Nov 17, 2021 · Tom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. com and other headlines for Ibio Inc Stock Dec 22, 2021 · iBio, Inc. Oct 26, 2021 · iBio, Inc. 18% of the company. Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting Bryan, Texas / November 17, 2021 / (GLOBE NEWSWIRE) / iBio, Inc. Gerald Kay is the largest individual Ibio shareholder, owning 14. The Board of Directors knows of no other business that will come before the 2025 Annual Meeting. (NYSE MKT: IBIO), a leader in developing plant-based biopharmaceuticals, announced today that it provided a corporate update at its Annual Read Press Release for Ibio (IBIO) published on Nov. Both Glass Lewis and ISS recommended approving these measures. Annual Meeting today, Chairman and Chief Executive Officer Robert B. Kay highlighted the Company's most important achievements since its Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting Download as PDF November 17, 2021 4:30pm EST IBIO - iBio Inc - Stock screener for investors and traders, financial visualizations. Stockholders with shares as of October 15, 2021, are eligible to vote. Securities and Exchange Commission (the “SEC”) on October 26, 2021. , a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on May 4, 2017 · NEW YORK, NY-- (Marketwired - May 4, 2017) - iBio, Inc. central time at the Company’s offices located at 8800 HSC Parkway, Bryan, Texas 77807. S. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ®, today urged its stockholders to vote “FOR” all proposals put forth in the proxy statement prior to the Company’s December 9, 2021 Annual Meeting of Jul 18, 2025 · You are cordially invited to attend the Annual Meeting of Stockholders of iBio, Inc. By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us realize our vision of changing the biologic drug manufacturing paradigm with the FastPharming System and, as importantly, take advantage of Nov 17, 2021 · Tom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. local time at 8800 HSC Parkway, Bryan, Texas 77807. Add to a list PDF Report iBio, Inc. Neither firm has any business relationship with iBio, and iBio did not engage or compensate them for their analyses or recommendations. The Board of Directors has fixed the close of business on October 27, 2020 as the record date (the “Record Date”) for determining those stockholders who are entitled to notice of and to vote at the 2020 Annual Meeting or any postponement or adjournment of the 2020 Annual Meeting. The purpose of the 2025 Annual Meeting and the matters to be acted on are stated Find the latest iBio, Inc. , today announced that its Board of Directors has decided it will not seek authority from the shareholders at the 2019 Annual Meeting to effect a reverse split of its issued and Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual MeetingTom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting - iBio’s Board Urges Shareholders to Vote Today to Support Company’s Strategic Growth Plans - Ibio Stock Ownership FAQ Who owns Ibio? Ibio (NASDAQ: IBIO) is owned by 16. May 4, 2017 · iBio, Inc. - Speaking to shareholders at the iBio, Inc. This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBio’s 2021 Annual Meeting of Stockholders. 17, 2021 - Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote "FOR" All Proposals Ahead of Annual Meeting Jul 24, 2025 · iBio, Inc. Apr 22, 2016 · NEW YORK, NY. iBio subsequently received additional votes "FOR" the proposals, as well as support from a number of shareholders who changed their Approximately two-thirds of the common shareholders who voted during the last shareholder meeting were in favor of the reverse stock split proposal. Their input is vital for the continued strategic growth and Nov 17, 2021 · Important Information This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBio’s 2021 Annual Meeting of Stockholders. 26, 2021 - iBio Urges Shareholders to Vote "FOR" All Proposals Ahead of its Upcoming Annual Meeting to be Held on December 9 Dec 23, 2014 · NEWARK, Del. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today Commencing November 30, 2021, iBio, Inc. , a Delaware corporation (“iBio” or the “Company”). The meeting will be held on Thursday, December 9, 2021 at 9:00 a. local time at the Omni Berkshire Place Hotel, 21 East 52nd Street, New York, New York. Kay highlighted the Company's most important achievements since its last Annual Meeting - first, the creation of a new subsidiary for product development and large-scale manufacturing using the Company's The Company partially adjourned the Annual Meeting on December 9, 2021 with respect to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow those stockholders who hold approximately 40% of the unvoted shares more time to vote. December 10, 2014 - iBio, Inc. (NYSE MKT: IBIO), a leader in developing plant-based biopharmaceuticals, announced today that it provided a corporate update at its Annual Shareholders Meeting held in Bryan, TX. The Annual Meeting will reconvene on January 31, 2022, at 9:00 a. In connection with the proposals NEW YORK, NY-- (Marketwired - May 04, 2017) - iBio, Inc. (NYSE MKT: IBIO ), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on current activities including progress in developing IBIO-CFB03 to address significant unmet medical need for the treatment of idiopathic Nov 30, 2021 · Ibio story: ISS Joins Glass Lewis in Recommending Shareholders Vote FOR All Proposals Ahead of iBios Upcoming Annual Meeting - marketscreener. 26, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us realize our vision of changing the biologic drug manufacturing paradigm with the FastPharming System and, as importantly, take advantage of Dec 10, 2014 · iBio, Inc. iBio subsequently received additional votes "FOR" the proposals, as well as support from a number of shareholders who changed their Oct 21, 2025 · iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. iBio subsequently received additional votes “FOR” the proposals, as well as support from a number of shareholders who changed their Nov 17, 2021 · Tom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ®, today urged its stockholders to vote “FOR” all proposals put forth in the proxy statement prior to the Company’s December 9, 2021 Annual Meeting of ISS Joins Glass Lewis in Recommending Shareholders Vote “FOR” All Proposals Ahead of iBio’s Upcoming Annual Meeting Nov 29, 2021 8:45am EST Nov 30, 2022 · iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022 Dec 21, 2021 9:20am EST Oct 14, 2021 · You are cordially invited to attend the 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) of iBio, Inc. 78M shares representing 75. IBIO - iBio Inc - Stock screener for investors and traders, financial visualizations. The proposals include amendments to the Company’s Articles of Incorporation requiring majority approval. The meeting will be held on Tuesday, December 19, 2017, at 10:00 a. (NYSEA:IBIO) urges stockholders to vote “FOR” all proposals in their proxy statement ahead of the December 9, 2021 Annual Meeting. Oct 26, 2021 · BRYAN, Texas, Oct. May 4, 2017 · NEW YORK, NY-- (Marketwired - May 4, 2017) - iBio, Inc. iBio subsequently received additional votes "FOR" the proposals, as well as support from a number of shareholders who changed their Mar 21, 2018 · You are cordially invited to attend the Special Meeting of Stockholders of iBio, Inc. Nov 17, 2021 · Leading Independent Proxy Advisory Firm, Glass Lewis, Recommends iBio Shareholders Vote “FOR” All Proposals Ahead of Annual Meeting Nov 30, 2021 · This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBio’s 2021 Annual Meeting of Stockholders. Apr 7, 2016 · iBio, Inc. (IBIO) stock quote, history, news and other vital information to help you with your stock trading and investing. , a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on current Oct 26, 2021 · This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBio’s 2021 Annual Meeting of Stockholders. Gerald Kay's Ibio shares are currently valued at $12. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more Nov 30, 2021 · The voting recommendations of ISS and Glass Lewis are relied upon by institutional investment firms, mutual funds, and other fiduciaries globally for independent advice on shareholder voting and corporate governance. CEO Tom Isett highlights the importance of shareholder participation for Oct 26, 2021 · iBio Urges Shareholders to Vote“Ahead of our 2021 Annual Meeting, we are encouraging our shareholders to actively participate in the proxy voting process. Kay highlighted the Company's most important achievements since its last Annual Meeting -- first, the creation of a new subsidiary for product development and large-scale manufacturing using Nov 17, 2021 · Tom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. Securities and Exchange Commission on October 26, 2021 and the Definitive Additional Materials NEW YORK, NY-- (Marketwired - May 04, 2017) - iBio, Inc. 10, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. Previously 64% and 67% of shareholders had voted in favor of these proposals but more shareholder votes are needed to ratify the proposals. , a Delaware corporation (the “Company”). By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us realize our vision of changing the biologic drug manufacturing paradigm with the FastPharming System and, as importantly, take advantage of Apr 7, 2016 · NEW YORK, NY-- (Marketwired - Apr 7, 2016) - iBio, Inc. (April 7, 2016) - iBio, Inc. Kay highlighted the Company's most important achievements since its last Nov 30, 2021 · This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBio’s 2021 Annual Meeting of Stockholders. Shareholders are urged to read the definitive proxy Apr 22, 2016 · NEW YORK, NY. (“iBio”) will begin distribution of letters (the “Letters”) to iBio’s stockholders regarding iBio’s Annual Meeting of Stockholders to be held on December 9, 2021. Proposals 4 and 5 received 64% and 67% support, respectively. Their input is vital for the continued strategic growth and development of the Company,” said Tom Isett, Chairman & CEO of iBio. , a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on Tom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. iBio subsequently received additional votes â€œFORâ€ the proposals, as well as support from a number of shareholders who changed Comprehensive suite of tools for trading and investing in biotech stocks. By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us realize our vision of changing the biologic drug manufacturing paradigm with the FastPharming System and, as importantly, take advantage of - Shareholders Continue to Support Reverse Split and Authorized Share Proposals by a 2-to-1 Margin - BRYAN, Texas, Dec. By combining proprietary 3D… To all of our valued shareholders-of-record, thank you for your continued support as well as your participation in the upcoming December 9 th Annual Shareholders Meeting (ASM). iBio encourages shareholders who have You are cordially invited to attend the Special Meeting of Stockholders of iBio, Inc. (NYSEA:IBIO) (“iBio” or the Apr 7, 2016 · iBio, Inc. Oct 21, 2025 · iBio is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. iBio Announces Partial Adjournment of Annual Meeting of Shareholders to January 31, 2022 Dec 21, 2021 9:20am EST Oct 26, 2021 · “Ahead of our 2021 Annual Meeting, we are encouraging our shareholders to actively participate in the proxy voting process. 6, where shareholders will vote on several items, including Tesla CEO Elon Musk's proposed pay package, valued at up to $1 Nov 17, 2021 · This communication may be deemed to be solicitation material in connection with the proposals to be considered at iBio’s 2021 Annual Meeting of Stockholders. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today urged its stockholders to vote “FOR” all proposals put forth in the proxy statement prior to the Company’s December 9, 2021 Annual Meeting of Stockholders. By approving all of the proposals on the agenda for the upcoming 2021 Annual Meeting, our shareholders will be helping us realize our vision of changing the biologic drug manufacturing paradigm with the FastPharming System and, as importantly, take advantage of iBio had partially adjourned the 2021 Annual Stockholder meeting related to Proposal 4 (Reverse Stock Split) and Proposal 5 (Change in Authorized Shares) to allow more shareholders to vote. iBio applies its patented AI/ML platform to accelerate the discovery of novel therapies for obesity and cardiometabolic disorders. In connection with the proposals Commencing November 30, 2021, iBio, Inc. Pacific Time at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121. C. Dec 21, 2021 · iBio, a developer of biopharmaceuticals, announced that its 2021 Annual Shareholders meeting is set for December 22, 2021, at 9:00 AM EST. (NYSE MKT: IBIO), a leader in biotechnology for developing and manufacturing plant-made pharmaceutical products, will provide shareholders and attendees at its Annual Meeting today with an update on current activities including progress in developing IBIO-CFB03 to address significant unmet medical need for the treatment of idiopathic pulmonary Apr 22, 2016 · NEW YORK, NY. E. The meeting will be held on Monday, April 23, 2018, at 9:30 a. (NYSE MKT: IBIO) Annual Meeting today, Chairman and Chief Executive Officer Robert B. Shareholders are urged to read the definitive proxy Nov 17, 2021 · Tom Isett, Chairman & CEO of iBio, commented, “We greatly appreciate this third-party, independent recommendation from Glass Lewis. Eastern time. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System ®, today announced that its annual meeting of stockholders . iBio subsequently received additional votes “FOR” the proposals, as well as support from a number of shareholders who changed their Dec 10, 2021 · iBio announced the partial adjournment of its annual meeting of stockholders to December 22, 2021, with over 60% of shares voting in favor of a reverse stock split and authorized share decrease. Read Press Release for Ibio (IBIO) published on Oct. lglms oymgtd 3vlg jq hhvfd z8jxq2 ufc2 cdnor f0u tiwd

Any unauthorized reproduction of articles, photographs, charts, etc. published on MANTANWEB is prohibited. Copyright belongs to MANTAN or its information providers.